Human Molecular Genetics Advance Access originally published online on July 1, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Human Molecular Genetics, 2003, Vol. 12, No. 16 2021-2030
DOI: 10.1093/hmg/ddg218
© 2003 Oxford University Press
Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release
1Department of Human Genetics, Emory University School of Medicine, Atlanta, GA 30322, USA and 2Department of Anatomy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, PR China
Received April 16, 2003; Revised June 16, 2003; Accepted June 23, 2003
In Huntington disease (HD), polyglutamine expansion causes the disease protein huntingtin to aggregate and accumulate in the nucleus and cytoplasm. The cytoplasmic huntingtin aggregates are found in axonal terminals and electrophysiological studies show that mutant huntingtin affects synaptic neurotransmission. However, the biochemical basis for huntingtin-mediated synaptic dysfunction is unclear. Using electron microscopy on sections of HD mouse brains, we found that axonal terminals containing huntingtin aggregates often had fewer synaptic vesicles than did normal axonal terminals. Subcellular fractionation and electron microscopy revealed that mutant huntingtin is co-localized with huntingtin-associated protein-1 (HAP1) in axonal terminals in the brains of HD transgenic mice. Mutant huntingtin binds more tightly to synaptic vesicles than does normal huntingtin, and it decreases the association of HAP1 with synaptic vesicles in HD mouse brains. Brain slices from HD transgenic mice that had axonal aggregates showed a significant decrease in [3H]glutamate release, suggesting that neurotransmitter release from synaptic vesicles was impaired. Taken together, these findings suggest that mutant huntingtin has an abnormal association with synaptic vesicles and this association impairs synaptic function.
* To whom correspondence should be addressed at: Department of Human Genetics, Emory University School of Medicine, 615 Michael Street, Atlanta, GA 30322, USA. Tel: +1 4047273290; Fax: +1 4047273949; Email: xiaoli{at}genetics.emory.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. R. Joshi, N.-P. Wu, V. M. Andre, D. M. Cummings, C. Cepeda, J. A. Joyce, J. B. Carroll, B. R. Leavitt, M. R. Hayden, M. S. Levine, et al. Age-Dependent Alterations of Corticostriatal Activity in the YAC128 Mouse Model of Huntington Disease J. Neurosci., February 25, 2009; 29(8): 2414 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-S. Her and L. S. B. Goldstein Enhanced Sensitivity of Striatal Neurons to Axonal Transport Defects Induced by Mutant Huntingtin J. Neurosci., December 10, 2008; 28(50): 13662 - 13672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Orr, S. Li, C.-E. Wang, H. Li, J. Wang, J. Rong, X. Xu, P. G. Mastroberardino, J. T. Greenamyre, and X.-J. Li N-Terminal Mutant Huntingtin Associates with Mitochondria and Impairs Mitochondrial Trafficking J. Neurosci., March 12, 2008; 28(11): 2783 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Milnerwood and L. A. Raymond Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load J. Physiol., December 15, 2007; 585(3): 817 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pardo, E. Colin, E. Regulier, P. Aebischer, N. Deglon, S. Humbert, and F. Saudou Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421 J. Neurosci., February 1, 2006; 26(5): 1635 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Benn, C. Landles, H. Li, A. D. Strand, B. Woodman, K. Sathasivam, S.-H. Li, S. Ghazi-Noori, E. Hockly, S. M.N.N. Faruque, et al. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease Hum. Mol. Genet., October 15, 2005; 14(20): 3065 - 3078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Petersen, J. Gil, M. L.C. Maat-Schieman, M. Bjorkqvist, H. Tanila, I. M. Araujo, R. Smith, N. Popovic, N. Wierup, P. Norlen, et al. Orexin loss in Huntington's disease Hum. Mol. Genet., January 1, 2005; 14(1): 39 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, T. H. Murphy, M. R. Hayden, and L. A. Raymond Enhanced Striatal NR2B-Containing N-Methyl-D-Aspartate Receptor-Mediated Synaptic Currents in a Mouse Model of Huntington Disease J Neurophysiol, November 1, 2004; 92(5): 2738 - 2746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Li and X.-J. Li Huntington and its Role in Neuronal Degeneration Neuroscientist, October 1, 2004; 10(5): 467 - 475. [Abstract] [PDF]
|
|
|
|
 |
|
 J. T. Kittler, P. Thomas, V. Tretter, Y. D. Bogdanov, V. Haucke, T. G. Smart, and S. J. Moss Huntingtin-associated protein 1 regulates inhibitory synaptic transmission by modulating {gamma}-aminobutyric acid type A receptor membrane trafficking PNAS, August 24, 2004; 101(34): 12736 - 12741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Schilling, A. V. Savonenko, A. Klevytska, J. L. Morton, S. M. Tucker, M. Poirier, A. Gale, N. Chan, V. Gonzales, H. H. Slunt, et al. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice Hum. Mol. Genet., August 1, 2004; 13(15): 1599 - 1610. [Abstract] [Full Text] [PDF]
|
|